UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest reported): ~~March~~April 3128, 2025

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-40089	59-3691650
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)
(State or other jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification Number)

11120 NE 2nd Street, Suite 100, Bellevue, WA 98004

(Address of principal executive offices)

(206) 617-9797

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 53.0201. ~~Departure~~Notice of ~~Directors~~Delisting or ~~Certain~~Failure ~~Officers;~~to ~~Election~~Satisfy ofa ~~Directors;~~Continued ~~Appointment~~Listing ofRule ~~Certain~~or ~~Officers~~Standard; ~~Compensatory~~Transfer ~~Arrangements~~ of ~~Certain~~ ~~Officers.~~Listing

As previously ~~disclosed~~reported, onThe ~~November~~Nasdaq 7,Stock ~~2024,~~Market ~~Robert~~LLC’s ~~Mattacchione~~(“Nasdaq”) ~~resigned~~Listing asQualifications ~~Chief~~Staff ~~Executive~~(the ~~Officer~~“Staff”) notified of Novo Integrated Sciences, Inc. (the “Company”), ~~effective~~that 90it ~~days~~was ~~following~~in ~~the~~violation ~~notification~~of ~~date~~the ~~(i.e.~~minimum ~~effective~~bid ~~February~~price 5,requirement of ~~2025~~Nasdaq Listing Rule 5550(a)(2). Also as previously disclosed, on November 4, 2024, the ~~effective~~Company ~~date~~received ofa ~~Mr.~~letter ~~Mattacchione~~from Nasdaq indicating that the Company’s ~~resignation~~common ~~was~~stock ~~subsequently~~would ~~extended~~be todelisted ~~February~~from Nasdaq and trading in the Company’s common stock would be suspended ~~20,~~at ~~2025~~the open of trading on November 6, ~~again~~2024. toBeginning noat ~~later~~the ~~than~~open ~~March~~of 7trading on November 6, ~~2025~~2024, ~~and~~the ~~again~~Company’s tocommon nostock ~~later~~began trading ~~than~~on ~~March~~the ~~31,~~OTC ~~2025~~Market under the symbol “NVOS.”

~~Thereafter,~~On onApril ~~March 31~~28, 2025, Nasdaq notified the Company ~~and~~that ~~Mr.~~it ~~Mattacchione~~would ~~agreed~~file toa ~~extend~~Form 25 with the ~~effective~~Securities ~~date~~and Exchange Commission to complete the delisting of ~~Mr.~~the ~~Mattacchione~~Company’s ~~resignation~~common tostock. ~~no later~~As ~~than~~of ~~April~~the ~~30,~~filing ~~2025~~time of this Current Report on Form 8-K, inthe ~~order~~Form to25 ~~provide~~has not yet been filed by Nasdaq. The delisting will be effective 10 days after the Form 25 is filed. The Company’s ~~the~~common ~~necessary~~stock ~~time~~will continue to ~~complete~~be anquoted ~~efficient~~on ~~transition~~the OTC Market following filing and effectiveness of the ~~Chief~~Form ~~Executive Officer position~~25.

Following Mr. Mattacchione’s departure as Chief Executive Officer, Mr. Mattacchione intends to continue to serve as (i) the Company’s Chairman of the Board, and (ii) Chairman of Novo Healthnet Limited, a wholly owned subsidiary of the Company. Mr. Mattacchione’s resignation was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Novo Integrated Sciences, Inc.
Dated: April 4, 2025	By:	/s/ Robert Mattacchione
Dated: May 2, 2025	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer

Filing Compare · Novo Integrated Sciences, Inc.